Cargando…
BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
BACKGROUND: The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in Latvia. This is significantly lower than the European average of 5–10%. Molecular markers like mutations and SNPs can help distinguish HBOC patients in the sporadic breast and ovarian cancer...
Autores principales: | Berzina, Dace, Nakazawa-Miklasevica, Miki, Zestkova, Jekaterina, Aksenoka, Karina, Irmejs, Arvids, Gardovskis, Andris, Kalniete, Dagnija, Gardovskis, Janis, Miklasevics, Edvins |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686592/ https://www.ncbi.nlm.nih.gov/pubmed/23767878 http://dx.doi.org/10.1186/1471-2350-14-61 |
Ejemplares similares
-
High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
por: Kalniete, Dagnija, et al.
Publicado: (2015) -
Challenges in the management of a patient with Cowden syndrome: case report and literature review
por: Melbārde-Gorkuša, Inga, et al.
Publicado: (2012) -
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014) -
Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Irmejs, Arvids, et al.
Publicado: (2008) -
The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population
por: Plonis, J, et al.
Publicado: (2016)